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Aim: To investigate the oxidative and antioxidative status in diabetic patients with cataracts and nondiabetic patients with cataracts as
compared to controls.
Materials and methods: There were 149 subjects included in the present study. Blood was collected from type 2 diabetic patients
suffering from cataracts (diabetic cataract; n = 42), senile nondiabetic patients suffering from cataracts (nondiabetic cataracts; n = 60),
and healthy subjects of a control group (n = 47). Serum levels of total oxidant status (TOS), total antioxidant status (TAS), total thiol
levels (TTLs), and paraoxonase 1 (PON1) were investigated in the samples.
Results: TTLs were significantly reduced in diabetic cataract patients (444.8 µmol/L) compared with both nondiabetic cataract patients
(525.1 μmol/L) and the control group (569.9 µmol/L). Plasma PON1 levels also were significantly reduced in diabetic cataract patients
(241.9 U/L) relative to the control group (178.3 U/L). There were no statistically significant differences between TAS and TOS levels
among groups.
Conclusion: The present study demonstrates a significant reduction in serum TTLs and serum PON1 activities in diabetic cataract
patients compared with controls. These findings represent a failure in the antioxidant system, which may be related to the cataractogenic
process.
Key words: Oxidative status, antioxidative status, diabetic cataract

1. Introduction
The process of cataractogenesis is complex and
multifactorial and is induced by number of risk factors
(1–3). Among these, diabetes has been implicated as
a major risk factor for the development of cataracts
(4,5). Many clinical, epidemiological, and preclinical
studies evaluating the relationship between diabetes and
cataractogenesis have shown that cataract formation
occurs more frequently, at earlier ages, and progresses
much faster in diabetic individuals compared with
nondiabetics (6,7) Although the cataractogenic effect of
diabetes has been demonstrated, the exact mechanism
is still unclear (8–10). Multiple pathogenic mechanisms,
such as increased oxygen free radical formation, abnormal
glycosylation of lens proteins, advanced glycation process,
and increased tissue sorbitol concentration, have been
proposed (11–13).
Oxidative stress induced by excessive reactive oxygen
species (ROS) has a detrimental role in all diabetic
complications, including diabetic cataracts (14). Oxidative
* Correspondence: drnagihanu@gmail.com
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stress status is defined as the production of larger amount
of ROS than can be scavenged or inactivated by available
antioxidant systems. In addition to damaging vital
biological molecules, such as DNA, cellular proteins, and
lipids, and leading to serious pathological results (15), it
has been considered for a long time that excessive amounts
of ROS have an important role in cataractogenesis (16).
Among various different parameters that have been
used to measure oxidative stress status, total oxidant status
(TOS) and total antioxidant status (TAS) are widely used
and safe markers for the evaluation of oxidative stress
levels (17,18) .
Antioxidants are molecules that protect cellular
components against free radical-induced oxidative
damage. There are many antioxidant systems in the human
body that deactivate the ROS. The effect of reduced levels
of antioxidant molecules on pathological processes in
many diseases has been extensively investigated (19). It has
been demonstrated that the concentration of antioxidant
molecules in serum and lenses is significantly reduced in
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cataract patients with diabetes compared with nondiabetic
cataract patients and controls (20,21).
Thiols are one of the most important members of the
antioxidant defense system (22,23).Significantly reduced
thiol levels have been reported in patients with exudative
age-related macular degeneration (ARMD) (24). To the
best of our knowledge, the plasma total thiol levels (TTLs)
in diabetic cataracts have never been investigated.
Paraoxonase is another important member of the
antioxidant defense system (25,26). Expression of
paraoxonase 1 (PON1) in the human diabetic cataractous
lens has been reported (27). Moreover, lower PON1 levels
in the serum of diabetic patients suffering from cataracts
were also reported (28). Based on these results it was
proposed that, within the lens, antioxidant properties of
PON1 may provide protection against oxidative stress. The
number of studies evaluating the effect of PON1 activities
in diabetic cataracts is very limited (27,28).
The aim of this study was to investigate the levels of
TOS, TAS, TTL, and PON1 in diabetic patients with
diabetic cataracts and nondiabetic cataract patients
compared to a control group.
2. Materials and methods
2.1. Subjects and sample collection
Our study population consisted of diabetic cataract
patients (n = 42), nondiabetic cataract patients (n = 60),
and healthy subjects as a control group (n = 47).
The study was conducted in the Department of
Ophthalmology, Ankara Atatürk Research and Training
Hospital. The study protocol was approved by the Ethics
Committee of the Atatürk Research and Training Hospital
and was conducted according to the Declaration of Helsinki
and Good Clinical Practice Guidelines. The participants
were informed about the nature of the study and informed
consent was obtained. All subjects were over 55 years of
age. Cataract types in the eyes of diabetic and nondiabetic
patients were nuclear. Subjects who had histories of
hypertension, cardiovascular disease, renal dysfunction,
hepatic disease, hypo- or hyperthyroidism, and traumatic
or toxic cataract were excluded from the study. None of the
subjects were taking vitamins or antioxidant supplements
or were smokers.
2.2. Samples
Blood samples were drawn into plain vacutainers from
the antecubital veins of healthy controls and patients. The
blood was allowed to clot for 30 min and serum specimens
were centrifuged for 10 min at 4000 rpm, transferred to
Eppendorf tubes, and stored at −80 °C until analysis.
2.3. Measurement of biochemical parameters
Serum hemoglobin (Hb), hemoglobin A1C (HbA1c),

apolipoprotein A (ApoA), and fibrinogen were measured
in the samples. Biochemical analyses were performed with
a routine chemistry laboratory (Cobas P8000 and C6000,
Roche Hitachi, Mannheim, Germany).
2.4. Measurement of paraoxonase activities
Paraoxonase activities were measured using paraoxon
substrate. The rate of paraoxon hydrolysis (diethyl-pnitrophenylphosphate) was measured by monitoring
the increase of absorbance at 412 nm at 37 °C on an
autoanalyzer (Advia 2400, Siemens, Japan). The amount
of generated p-nitrophenol was calculated from the molar
absorption coefficient at pH 8, which was 17,000 M–1 cm–1
(29). Paraoxonase activity was expressed as U/L.
2.5. Measurement of total oxidant status
The TOS levels of the sera were determined using a novel
automated measurement method (17). Oxidants present
in the sample oxidize ferrous o-dianisidine complexes
into ferric ions. The oxidation reaction was enhanced
by glycerol molecules that are abundantly present in the
reaction medium. The ferric ions form a colored complex
with xylenol orange as an acidic medium. Therefore, the
color intensity, measured spectrophotometrically, was
related to the total number of oxidant molecules present
in the sample. The assay was calibrated with hydrogen
peroxide and the results were expressed in terms of
micromolar hydrogen peroxide equivalent per liter (µmol
H2O2 equiv/L).

2.6. Measurement of total antioxidant status
The TAS of sera was measured using an automated
colorimetric measurement method for TAS developed by
Erel (18). In this method, the hydroxyl radical, the most
potent biological radical, is produced by the Fenton reaction
and it reacts with the colorless substrate O-dianisidine to
produce the dianisyl radical, which is bright yellowishbrown in color. Upon the addition of a plasma sample,
the oxidative reactions initiated by the hydroxyl radicals
present in the reaction are suppressed by the antioxidant
components of the plasma, preventing the color change
and thereby providing an effective measurement of TAS.
The assay results were expressed as mmol Trolox equiv/L.
2.7. Measurement of total thiol status
TTL serum concentrations or sulfhydryl groups (-SH) were
measured by the methods originally described by Elmman
(30) and modified by Hu (31). Here, thiols interact with
5,5’-dithiobis-(2-nitrobenzoic acid), forming a highly
colored anion with a maximum peak at 412 nm. Here,
this method was adapted to an automated biochemistry
analyzer for the first time (Advia 2400, Siemens, Japan).
2.8. Statistics
Data analysis was performed by using SPSS 11.5 for
Windows (SPSS Inc., Chicago, IL, USA). Data were
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shown as mean ± SD or mean (95% confidence interval
[CI]). Whether the mean differences among groups were
statistically significant or not was evaluated by analysis
of covariance (ANCOVA) after adjustment for age.
According to the ANCOVA, while the clinical parameters
were assumed as dependent variables, study groups and
age were assumed as a fixed factor and a covariate factor,
respectively. The Bonferroni adjusted multiple comparison
test was applied for determining which group differed from
which others. A P-value of less than 0.05 was considered
statistically significant.
3. Results
Patients’ biochemical parameters examined during
the research are shown in Table 1. Overall, the level of
fibrinogen and ApoA were significantly reduced in diabetic
cataract patients compared to the control group. HbA1c
levels were significantly higher in the diabetic cataract
group compared to both nondiabetic cataract patients and

the control group. Similar results were also observed for
Hb levels.
TTL, PON, TAS, and TOS levels are presented in
Table 2. Overall, TTLs were significantly reduced in
diabetic cataract patients (P < 0.001) compared with both
nondiabetic cataract patients and the control group. There
were also statistically significant differences between thiol
levels in nondiabetic cataract patients and the control
group (P < 0.05) (Figure 1).
Plasma PON1 activities were significantly reduced in
diabetic cataract patients relative to the control group (P
< 0.05). Although PON1 activities in these subjects were
also reduced compared to nondiabetic cataract patients,
the difference was not clinically significant. Similar results
were also observed between nondiabetic subjects with
cataracts and the control group (Figure 2). There were
no statistically significant differences between TAS (P =
0.126) and TOS (P = 0.254) levels among groups.

Table 1. Biochemical parameters of study groups (mean ± SD).
Variables

Controls
(n = 47)

Nondiabetic cataracts
(n = 60)

Diabetic cataracts
(n = 42)

P-value

Fibrinogen (mg/dL)

295.8 (255.8–335.8)

355.8 (322.5–389.2)

407.8 (370.1–445.5)

<0.001

ApoA (mg/dL)

147.4 (137.1–157.6)

136.3 (128.0–144.6)

123.6 (114.1–133.1)

0.005

HbA1c (%)

5.67 (5.33–6.04)

5.85 (5.56–6.14)

7.33 (7.01–7.66)

<0.001

Folic acid (ng/mL)

9.6 (8.5–10.6)

7.8 (6.9–8.7)

9.4 (8.4–10.4)

0.018

Hb (g/dL)

13.9 (13.4–14.4)

13.8 (13.4–14.2)

12.8 (12.4–13.3)

<0.001

ApoA: apolipoprotein A, HbA1c: hemoglobin A1c, HB: hemoglobin.

Table 2. Enzyme levels of study groups (mean ± SD).
Variables

Controls
(n = 47)

Nondiabetic
cataracts (n = 60)

Diabetic cataracts
(n = 42)

P-value

TTL (µmol/L)

569.9 (544.6–595.3)

525.1 (504.3–545.8)

444.8 (421.0–468.6)

<0.001

PON (U/L)

241.9 (209.8–274.1)

202.5 (176.2–228.8)

178.3 (148.1–208.5)

0.024

TAS (mmol Trolox equiv/L)

2.81 (2.70–2.92)

2.69 (2.61–2.78)

2.82 (2.72–2.93)

0.126

TOS (μmol H2O2 equiv/L)

14.6 (12.9–16.4)

15.1 (13.7–16.6)

13.3 (11.7–15.0)

0.254

TTL: total serum thiol levels, PON: serum paraoxonase activity, TOS: total serum oxidant status, TAS: total serum antioxidant status.
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Figure 1. TTLs of study groups.

Figure 2. PON1 activities of study groups.

4. Discussion
The results of the present study showed that serum TTL
and PON1 levels were significantly lower in patients
with diabetic cataracts compared with the control group.
Statistically significant differences were also observed
between TTLs of diabetic cataract patients and nondiabetic
cataract patients. There were no significant differences in
TAS and TOS levels in any of the groups.
Plasma TTLs indicate the total amount of thiolcarrying molecules in the plasma. Thiols are sulfhydryl
groups (-SH) containing derivatives that have important
biological functions (32). They are important in protein
structure and function, in regulation of enzymatic activity
and in transcriptional activity, and are also one of the
most efficient members of the antioxidant defense system
(22,23). Various characteristic features of thiols contribute
to their powerful antioxidant properties, one of which is
their ability to neutralize ROS.
ROS are essential molecules for the regulation of vital
cellular functions; however, overproduction of them may
damage vital biological molecules including proteins,
lipids, and nucleic acids, leading to various pathological
conditions (15). In lens tissue, excessive amounts of
ROS lead to biochemical changes such as degradation,
crosslinking, and aggregation of lens proteins; these may
have an important role in cataractogenesis (16).
The exact source of ROS in lens tissue is not clearly
defined but hyperglycemia in diabetes is one of the
major contributors. Hyperglycemia in diabetes increases
generation of ROS and directly induces oxidative stress.
Increased production of ROS in diabetes has been
implicated in the pathogenesis of diabetic complications
(33). In lens tissue, excessive ROS initiates lipid
peroxidation and, together with glycation of proteins,
induces biochemical reactions that lead to lens fiber
damage and light scattering (4,13).

The rates of production and removal of ROS are
strictly regulated to maintain the physiological levels.
To protect this sensitive balance, several enzymatic and
nonenzymatic antioxidant mechanisms in the body work
in order to deactivate the excessive ROS efficiently (19).
Several antioxidant molecules being taken through diet
also play a role in the deactivation process and provide
protection against ROS-induced oxidative injury (34–
37).
In various pathological conditions, such as stroke,
coronary artery diseases, and liver failure, decreased level
of thiols have been observed (38–41).
Low thiol levels were also observed in wet-type ARMD
patients compared with the control group (24). To the
best of our knowledge, plasma TTL levels have not been
studied previously in cataract patients.
Paraoxonase is another important antioxidant enzyme
that protects low-density lipoprotein from oxidation
and has a role in detoxification of organophosphates.
Significantly reduced PON1 activities have been reported
in hyperthyroidism (42), diabetes (43), cardiovascular
diseases (44), chronic renal failure (45), and age-related
macular degeneration (46).
Hashim et al. evaluated the serum PON1 activities
in diabetic and nondiabetic patients with cataracts and
observed significantly reduced PON1 levels in both groups
compared with the control group (27). Hashim et al. also
demonstrated the expression of PON1 at the genetic and
proteomic levels in human lens tissue and proposed that
PON1 has an antioxidant role against oxidative stress (28).
The results of the present study support the findings of
Hashim et al.’s first study. We also observed significantly
reduced PON1 activities in diabetic cataract patients
compared with controls. PON1 activities in nondiabetic
cataract patients were also reduced, but the difference
was not statistically significant. The decrease in PON1
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activities may be due to several factors. First, high glucose
concentrations may be one of factors, because it was
shown that diabetic patients have lower PON1 levels. In
addition, PON1 activity is also lower in healthy subjects
with elevated fasting glucose levels and in patients with
metabolic syndromes (47,48). Second, reduction in
PON1 activity may also develop as a result of increased
ROS concentration (49). Jaouad et al. demonstrated that
PON1 activity is significantly reduced after exposure to
ROS (50), and so the lower PON1 levels that we observed
may reflect high ROS concentrations. Moreover, we
propose that reduced thiol levels are another factor that
contributes to the decrease in PON1 activity. PON1 has
a cysteine thiol group in its active site, which is necessary
for PON1 activity (32). At low thiol levels, the availability
of the thiol group for PON1 activity is decreased and
this causes a decrease in PON1 activity (32). Whatever
the cause, it is clear that in diabetic cataract patients
PON1 activity was significantly reduced. Together with
the reduced thiol levels, the results of the present study
demonstrated that serum levels of 2 important antioxidant
molecules are significantly decreased in diabetic patients
with cataracts.

ROS are very unstable molecules and they have a very
short half-life (6–10 s or less), and so their plasma or
tissue concentration cannot be directly measured; instead,
oxidative stress status is measured.
There are many studies in the literature that investigate
the oxidative stress parameters in diabetic cataract patients
(21,22). In our study, although TOS levels were similar in
cataract patients and controls, TTLs were significantly
lower in cataract patients. As mentioned above, thiols are a
primary component of the physiological antioxidant defense
system, and PON1 is another important member of this
system; we suggest that there was a state of oxidative stress
and ROS had increased. In response to excess ROS, thiols, as
a primary antioxidant, were consumed and PON1 activity
was also decreased. We propose that oxidative stress was
compensated for and TOS was maintained at a normal level.
In conclusion, the levels of 2 important antioxidant
molecules were significantly reduced in diabetic cataract
patients compared with controls. This finding represents
a decrease in the antioxidant defense system. Although no
differences were found between levels of TOS and TAS,
the decrease in antioxidant status may reflect that the
increased ROS concentration induced oxidative stress.
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